IBM Stacks Up Quantum Alliances and a $1 Billion Chip Subsidy While the Stock Slogs Through a 22% Annual Loss

IBM closed a $1 billion CHIPS award for quantum R&D in Albany, matching it with $1 billion, as shares fell 2.5% to EUR 201.90.

IBM has spent the past several weeks assembling a quantum-computing ecosystem that stretches from a Swiss research campus to a wafer fab in upstate New York — a build-out that management is funding through both private capital and federal money. The company finalized a $1 billion award with the U.S. Department of Commerce under the CHIPS and Science Act on Wednesday, with the funds routed through its Anderon unit. The money is earmarked for research and development at IBM's 300-millimeter quantum chip manufacturing facility in Albany, New York. IBM is matching that sum with another $1 billion of its own.

The confirmation of government backing did not lift the shares. According to media reports, some market participants used the news as an opportunity to lock in gains. By Friday's close, IBM stock had shed 2.5% to settle at EUR 201.90, extending its year-to-date decline to 22%.

A Swiss Hub and a Software Tie-Up

IBM's push into quantum extends well beyond fabrication. On September 10, the company and Lockheed Martin unveiled a joint quantum technology innovation center at ETH Zurich. The initiative is designed to move quantum applications out of research labs and into practical deployment. A day earlier, LTM had announced a collaboration with IBM and its Red Hat subsidiary centered on the Lightwell project.

The hardware side kept pace. On September 3, IBM reported a 25-fold increase in throughput for quantum computations. On the policy front, IBM joined Microsoft roughly two weeks ago in backing the American Quantum Competitiveness Act, after a U.S. House of Representatives committee advanced the legislative effort.

Governance Software Gets a Regulatory Feed

IBM is also expanding what its software can do. The company and specialist CUBE said Thursday they will work together to deliver automated monitoring for AI regulation worldwide. The new capability, called Regulatory Horizon Scanning, will be embedded directly into IBM watsonx.governance, giving enterprises a continuous read on regulatory shifts affecting their AI systems across jurisdictions.

The feature addresses a growing pain point for multinationals, which face a patchwork of country-specific rules governing algorithms and automated decision-making. By folding CUBE's regulatory database into watsonx.governance, IBM aims to help clients build legal requirements into their development and operating models early.

Research Acquisition Closes

IBM's hardware and foundational research efforts got a boost on August 26, when the company completed its acquisition of HRL Laboratories, LLC. The research institute brings expertise in silicon spin qubits, complementing IBM's focus on superconducting quantum computers. HRL's portfolio also spans quantum sensing, materials science, and electronic interconnect and control technologies.

A Bruised Core and a Wait for Clarity

The operational flurry has yet to show up in the share price. IBM came under pressure back in July after reporting second-quarter results: adjusted earnings of $2.93 per share and revenue of $17.16 billion fell short of the then-current market estimates of $3.01 per share and $17.86 billion, respectively. Management subsequently trimmed its full-year revenue growth forecast to a range of 4% to 5% — a target the company reiterated at the time of its second-quarter report.

Not everyone has turned cautious. Susquehanna raised its price target on the stock to $235 on August 31.

Investors will get their next read on the business on October 21, 2026, when IBM reports its next quarterly results.